Menu

Σύνδεση Μέλους

Κλινικές Μελέτες

A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1-3 prior lines of therapy

Protocol No
79635322MMY3002/TRIlogy-5

Trial information

Medical condition
MM
Trial phase
Phase 3
Sponsor
J&J
Start date
17/07/2026
End date
End of 2030
Main objective
To compare the efficacy and safety of JNJ-79635322 versus teclistamab in participants with relapsed/refractory multiple myeloma after 1–3 prior lines of therapy.

Locations and Contact points

Greece

Site city Organisation name Department name Name Email Telephone number
Ioannina University General Hospital of Ioannina Department of Hematology, Clinical Studies Office Eleftheria Hatzimichael
Olga Siarabi 2651099650